Identification of a protein S-interactive site within the A2 domain of the factor VIII heavy chain

Summary

We have recently demonstrated that protein S impairs the intrinsic tenase complex, independent of activated protein C, in competitive interactions between the A2 and A3 domains of factor VIIIa and factor IXa. In the present study, we have identified a protein S-interactive site in the A2 domain of factor VIIIa. Anti-A2 monoclonal antibody recognising a factor IXa-functional region (residues 484–509) on A2, and synthetic peptide inhibited the A2 binding to protein S by ∼60% and ∼70%, respectively, in solid-phase binding assays. The 484–509 peptide directly bound to protein S dose-dependently. Covalent cross-linking was observed between the 484–509 peptide and protein S following reaction with EDC (1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide). The cross-linked adduct was consistent with 1:1 stoichiometry of reactants. Cross-linking formation was blocked by addition of the 484–497 peptide, but not by the 498–509 peptide. Furthermore, N-terminal sequence analysis of the 484–509 peptide-protein S adduct showed that three sequential residues (S488, R489, and R490) in A2 were not identified, suggesting that these residues participate in cross-link formation. Mutant A2 molecules where these residues were converted to alanine were evaluated for the binding of protein S. The S488A, R489A, and R490A mutants demonstrated ∼four-fold lower affinity than wild-type A2.These results indicate that the 484–509 region in the A2 domain of factor VIIIa, in particular sequential residues at positions 488–490, contributes to a unique protein S-interactive site.

Keywords

Factor VIII(a) - protein S - A2 domain - binding-site - EDC crosslinking

• References

• 1 Mann KG, Nesheim ME, Church WR. et al. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood 1990; 76: 1-16.
• 2 Wood WI, Capon DJ, Simonsen CC. et al. Expression of active human factor VIII from recombinant DNA clones. Nature 1984; 312: 330-337.
• 3 Vehar GA, Keyt B, Eaton D. et al. Structure of human factor VIII. Nature 1984; 312: 337-42.
• 4 Fay PJ, Anderson MT, Chavin SI. et al. The size of human factor VIII heterodimers and the effects produced by thrombin. Biochim Biophys Acta 1986; 871: 268-278.
• 5 Lollar P, Hill-Eubanks DC, Parker CG. Association of the factor VIII light chain with von Willebrand factor. J Biol Chem 1988; 263: 10451-10455.
• 6 Foster PA, Fulcher CA, Houghten RA. et al. An immunogenic region within residues Val1670-Glu1684 of the factor VIII light chain induces antibodies which inhibit binding of factor VIII to von Willebrand factor. J Biol Chem 1988; 263: 5230-5234.
• 7 Saenko EL, Shima M, Rajalakshmi KJ. et al. A role for the C2 domain of factor VIII in binding to von Willebrand factor. J Biol Chem 1994; 269: 11601-11605.
• 8 Eaton D, Rodriguez H, Vehar GA. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry 1986; 25: 505-512.
• 9 Fay PJ. Activation of factor VIII and mechanisms of cofactor action. Blood Rev 2004; 18: 1-15.
• 10 Fay PJ, Mastri M, Koszelak ME. et al. Cleavage of factor VIII heavy chain is required for the functional interaction of a2 subunit with factor IXa. J Biol Chem 2001; 276: 12434-12439.
• 11 Regan LM, Fay PJ. Cleavage of factor VIII light chain is required for maximal generation of factor VIIIa activity. J Biol Chem 1995; 270: 8546-8552.
• 12 Donath MS, Lenting PJ, van Mourik JA. et al. The role of cleavage of the light chain at positions Arg1689 or Arg1721 in subunit interaction and activation of human blood coagulation factor VIII. J Biol Chem 1995; 270: 3648-3655.
• 13 Lamphear BJ, Fay PJ. Proteolytic interactions of factor IXa with human factor VIII and factor VIIIa. Blood 1992; 80: 3120-3126.
• 14 Nogami K, Shima M, Matsumoto T. et al. Mechanisms of plasmin-catalyzed inactivation of factor VIII: a crucial role for proteolytic cleavage at Arg336 responsible for plasmin-catalyzed factor VIII inactivation. J Biol Chem 2007; 282: 5287-5295.
• 15 DiScipio RG, Davie EW. Characterisation of protein S a gamma-carboxyglutamic acid containing protein from bovine and human plasma. Biochemistry 1979; 18: 899-904.
• 16 Walker FJ. Regulation of activated protein C by a new protein. A possible function for bovine protein S. J Biol Chem 1980; 255: 5521-5524.
• 17 Comp PC, Esmon CT. Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med 1984; 311: 1525-1528.
• 18 Bertina RM. Hereditary protein S deficiency. Haemostasis 1985; 15: 241-246.
• 19 Heeb MJ, Mesters RM, Tans G. et al. Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C. J Biol Chem 1993; 268: 2872-2832.
• 20 Heeb MJ, Rosing J, Bakker HN. et al. PS binds to and inhibits FXa. Proc. Natl. Acad. Sci 1994; 91: 2728-2727.
• 21 Hackeng T, Sere KM, Tans G. et al. PS stimulates inhibition of the tissue factor pathway by TFPI. Proc. Natl. Acad. Sci 2006; 103: 3106-3111.
• 22 Rosing J, Maurissen LFA, Tchaikovski SN. et al. Protein S is a cofactor for tissue factor pathway inhibitor. Thromb Res 2008; 122 (Suppl. 01) S60-63.
• 23 Koppelman SJ, Hackeng TM, Sixma JJ. et al. Inhibition of the intrinsic factor X activating complex by protein S: evidence for a specific binding of protein S to factor VIII. Blood 1995; 86: 1062-1071.
• 24 Takeyama M, Nogami K, Saenko EL. et al. Protein S down-regulates factor Xase activity independent of activated protein C: specific binding of factor VIII(a) to protein S inhibits interactions with factor IXa. Br J Haematol 2008; 143: 409-420.
• 25 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
• 26 Healey JF, Lubin I, Nakai H. et al. Residues 484–508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII. J Biol Chem 1995; 270: 14505-14509.
• 27 Sarafanov AG, Makogonenko EM, Pechik IV. et al. Identification of coagulation factor VIII A2 domain residues forming the binding epitope for low-density lipoprotein receptor-related protein. Biochemistry 2006; 45: 1829-1840.
• 28 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685.
• 29 Fay PJ, Scandella D. Human inhibitor antibodies specific for the factor VIII A2 domain disrupt the interaction between the subunit and factor IXa. J Biol Chem 1999; 274: 29826-29830.
• 30 Nogami K, Lapan KA, Zhou Q. et al. Identification of a factor Xa-interactive site within residues 337–372 of the factor VIII heavy chain. J Biol Chem 2004; 279: 15763-15771.
• 31 Carraway KL, Koshland DE. Carbodiimide modification of proteins. Meth Enzym 1972; 25: 616-623.
• 32 O’Brien LM, Huggins CF, Fay PJ. Interacting regions in the A1 and A2 subunits of factor VIIIa identified by zero-length cross-linking. Blood 1997; 90: 3943-3950.
• 33 Nogami K, Nishiya K, Saenko EL. et al. Identification of a plasmin-interactive site within the A2 domain of the factor VIII heavy chain. Biochim Biophys Acta 2008; 1784: 753-763.
• 34 Nogami K, Saenko EL, Takeyama M. et al. Identification of a thrombin-interactive site within the FVIII A2 domain that is responsible for the cleavage at Arg372. Br J Haematol 2008; 140: 433-443.
• 35 Jenkins PV, Dill JL, Zhou Q. et al. Clustered basic residues within segment 484–510 of the factor VIIIa A2 subunit contribute to the catalytic efficiency for factor Xa generation. J Thromb Haemost 2004; 02: 452-458.
• 36 Fay PJ, Beattie T, Huggins CF. et al. Factor VIIIa A2 subunit residues 558–565 represent a factor IXa interactive site. J Biol Chem 1994; 269: 20522-20527.
• 37 Jenkins PV, Dill JL, Zhou Q. et al. Contribution of factor VIIIa A2 and A3-C1-C2 subunits to the affinity for factor IXa in factor Xase. Biochemistry 2004; 43: 5094-5101.
• 38 Fersht AR, Shi JP, Knill-Jones J. et al. Hydrogen bonding and biological specificity analysed by protein engineering. Nature 1985; 314: 235-238.
• 39 Pemberton S, Lindley P, Zaitsev V. et al. A molecular model for the triplicated A domains of human factor VIII based on the crystal structure of human ceruloplasmin. Blood 1997; 89: 2413-2421.
• 40 Church WR, Jernigan RL, Toole J. et al. Coagulation factors V and VIII and ceruloplasmin constitute a family of structurally related proteins. Proc Natl Acad Sci USA 1984; 81: 6934-6937.
• 41 Heeb MJ, Kojima Y, Hackeng TM. et al. Binding sites for blood coagulation factor Xa and protein S involving residues 493–506 in factor Va. Protein Sci 1996; 05: 1883-1889.
• 42 Fernández JA, Heeb MJ, Griffin JH. Identification of residues 413–433 of plasma protein S as essential for binding to C4b-binding protein. J Biol Chem 1993; 268: 16788-16794.
• 43 Linse S, Härdig Y, Schultz DA. et al. A region of vitamin K-dependent protein S that binds to C4b binding protein (C4BP) identified using bacteriophage peptide display libraries. J Biol Chem 1997; 272: 14658-14665.
• 44 Heeb MJ, Kojima Y, Rosing J. et al. C-terminal residues 621–635 of protein S are essential for binding to factor Va. J Biol Chem 1999; 274: 36187-36192.